Virtu Financial LLC Reduces Holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Virtu Financial LLC lowered its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 93.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,624 shares of the company’s stock after selling 253,313 shares during the period. Virtu Financial LLC’s holdings in Atossa Therapeutics were worth $118,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC bought a new stake in shares of Atossa Therapeutics in the second quarter worth $192,000. Legal & General Group Plc acquired a new position in shares of Atossa Therapeutics during the second quarter valued at $74,000. California State Teachers Retirement System bought a new stake in shares of Atossa Therapeutics during the second quarter valued at about $1,019,000. Millennium Management LLC bought a new stake in shares of Atossa Therapeutics during the second quarter valued at about $10,535,000. Finally, BNP Paribas Arbitrage SA bought a new stake in shares of Atossa Therapeutics during the second quarter valued at about $66,000. Institutional investors own 28.18% of the company’s stock.

Shares of NASDAQ ATOS opened at $2.29 on Thursday. Atossa Therapeutics, Inc. has a fifty-two week low of $0.81 and a fifty-two week high of $9.80. The firm’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $3.77. The stock has a market cap of $289.97 million, a P/E ratio of -2.22 and a beta of 2.03.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, November 15th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65.

Read More: Beta

Institutional Ownership by Quarter for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.